Preclinical tumor models serve as the critical bridge between in vitro discovery and clinical translation, enabling researchers to evaluate therapeutic efficacy, safety profiles, and mechanistic insights in physiologically relevant systems. Alfa Cytology delivers end-to-end preclinical oncology solutions—from model selection and in vivo pharmacology to advanced molecular profiling—empowering your pipeline with robust, IND-enabling data.
The Landscape of Preclinical Oncology Research
Preclinical oncology research relies on a diverse array of tumor models to simulate human malignancy and predict therapeutic responses. These models span cell line-derived xenografts (CDX), patient-derived xenografts (PDX), genetically engineered mouse models (GEMM), syngeneic models, and humanized immune system models, each offering distinct advantages in immunogenicity, genetic fidelity, and clinical translatability. Comprehensive preclinical evaluation integrates in vivo pharmacology, pharmacokinetic (PK) and pharmacodynamic (PD) assessments, biomarker analysis, histopathology, flow cytometry, next-generation sequencing (NGS), and multi-omics profiling to generate mechanistic insights and guide clinical development decisions.
Fig 1. Preclinical immuno-oncology models. (Wang, Yufei, et al., 2022)
The convergence of advanced imaging modalities—such as bioluminescence imaging (BLI), micro-CT, MRI, and optical imaging—with molecular profiling technologies has transformed preclinical oncology from simple efficacy screening into a precision-driven discipline. Modern platforms now enable real-time monitoring of tumor growth, metastasis, and drug distribution, while combination therapy exploration platforms facilitate the rational design of multi-agent regimens that mirror contemporary clinical protocols. These integrated approaches ensure that preclinical data packages are not only statistically robust but also biologically meaningful, thereby reducing attrition rates and accelerating the transition from bench to bedside.
Integration of Multi-Platform Biomarker Strategies in Immuno-Oncology
The rapid evolution of immuno-oncology has underscored the necessity of integrating multiple analytical platforms to comprehensively characterize tumor biology and immune responses. No single modality can fully capture the complexity of the tumor microenvironment; therefore, researchers increasingly combine flow cytometry, immunohistochemistry/immunofluorescence (IHC/IF), and next-generation sequencing (NGS) to construct multidimensional biomarker profiles. Flow cytometry enables high-throughput immunophenotyping and functional immune analysis, IHC/IF provides spatial context and protein localization within tissue architecture, and NGS delivers deep molecular insights into genomic alterations, tumor mutational burden (TMB), and immune repertoire dynamics. This multi-platform approach has become the gold standard for biomarker-driven patient stratification and therapeutic response prediction in contemporary oncology trials.
The following table summarizes the complementary roles of these platforms in immuno-oncology biomarker assessment:
| Platform |
Primary Application |
Key Strengths |
Typical Biomarkers |
| Flow Cytometry |
Immunophenotyping & functional immune analysis |
High-throughput; multiparametric; single-cell resolution |
CD8+/CD4+ T cells, NK cells, Tregs, myeloid-derived suppressor cells, cytokine production |
| IHC/IF |
Spatial protein detection & tissue architecture |
Preserves tissue context; cost-effective; widely accessible |
PD-L1, CD8 infiltration, tumor-associated macrophages, vascular markers |
| NGS |
Genomic profiling & molecular characterization |
Comprehensive genomic coverage; detects rare variants; high sensitivity |
TMB, MSI, dMMR, TCR/BCR repertoire, gene fusions, mutational signatures |
| Multi-omics Integration |
Systems-level biomarker discovery |
Correlates cellular, spatial, and genomic data; AI-enhanced analysis |
Transcriptomic signatures, proteomic panels, metabolomic profiles |
Our Services
At Alfa Cytology, we understand that every therapeutic candidate demands a tailored preclinical strategy. Our integrated service platform combines validated tumor models with cutting-edge analytical technologies to deliver comprehensive data packages that meet global regulatory standards. Whether you are advancing a small molecule, biologic, antibody-drug conjugate (ADC), or cell therapy, our multidisciplinary team provides the scientific rigor and operational flexibility required to accelerate your oncology pipeline from lead optimization to IND submission.
Our in vivo pharmacology platform encompasses a broad spectrum of tumor-bearing animal models, including subcutaneous and orthotopic xenografts, syngeneic models, humanized immune system models, and metastasis models. We design and execute customized efficacy studies that evaluate tumor growth inhibition, survival benefit, and mechanistic endpoints tailored to your therapeutic modality. Study designs incorporate tolerability assessment, dose-response characterization, and combination regimen evaluation, with tumor growth kinetics, body weight monitoring, and humane endpoint survival analysis as standard readouts. Our scientists have hands-on experience across more than 200 preclinical oncology models, ensuring robust, reproducible data generation for IND-enabling packages.
Understanding the absorption, distribution, metabolism, and excretion (ADME) profile of oncology drug candidates is essential for dose selection and safety margin determination. We provide comprehensive PK analysis services including in vivo PK/PD modeling, toxicokinetic assessment, bioavailability determination, and drug-drug interaction (DDI) screening. Our bioanalytical capabilities support both small molecules and biologics, utilizing LC-MS/MS, ligand-binding assays (LBA), and hybrid methodologies to quantify drug concentrations in plasma, serum, tumor tissue, and other biological matrices. PK/PD integration enables correlation of systemic exposure with pharmacodynamic biomarkers, facilitating mechanistic understanding and dose optimization.
Biomarker analysis is central to modern oncology drug development, providing critical insights into target engagement, mechanism of action, and patient stratification. We offer a comprehensive suite of biomarker assays spanning soluble protein detection (ELISA, MSD), enzymatic activity measurements, and circulating biomarker monitoring in blood, serum, plasma, and tumor interstitial fluid. Our biomarker services are designed to support both exploratory research and validated diagnostic applications, with rigorous assay development, qualification, and validation protocols aligned with regulatory guidance.
IHC and IF remain the cornerstone techniques for spatial protein detection and tissue-based biomarker assessment in preclinical oncology. Our histopathology platform offers conventional chromogenic IHC, multiplex immunofluorescence (mIF), and advanced digital pathology solutions with AI-assisted image analysis. We support target antigen expression profiling (e.g., HER2, TROP2, PD-L1), immune cell infiltration mapping, tumor microenvironment characterization, and quantitative scoring algorithms including H-score and tumor proportion score (TPS). All protocols are optimized for rodent and human tissue specimens, ensuring cross-species translatability of histopathological findings.
Flow cytometry enables rapid, multiparametric analysis of immune cell populations at the cell level, making it indispensable for immuno-oncology and cell therapy development. Our platform supports conventional multicolor flow cytometry (8–18 colors), high-parameter spectral cytometry (>20 markers), and fluorescence-activated cell sorting (FACS) for downstream functional assays. Applications include immunophenotyping of tumor-infiltrating lymphocytes (TILs), exhaustion marker profiling (PD-1, TIM-3, LAG-3), cytokine secretion analysis, proliferation assays, and CAR-T cell persistence monitoring. Standardized protocols and rigorous quality control ensure reproducible data across longitudinal studies and multi-site programs.
Next-generation sequencing (NGS) provides unprecedented depth and breadth of genomic information, enabling comprehensive molecular profiling of preclinical tumor models. Our NGS services include whole-exome sequencing (WES), whole-genome sequencing (WGS), targeted panel sequencing, RNA sequencing (RNA-seq), and cell RNA sequencing. We deliver actionable insights on tumor mutational burden (TMB), microsatellite instability (MSI), DNA mismatch repair deficiency (dMMR), gene fusions, copy number alterations, and immune repertoire profiling (TCR/BCR sequencing). Bioinformatics pipelines are customized to project needs, with variant annotation, pathway enrichment analysis, and integration with clinical databases to support translational research.
Beyond genomics, our multi-omics platform integrates transcriptomics, proteomics, metabolomics, and epigenomic profiling to construct systems-level understanding of tumor biology and drug response. Transcriptomic analysis via RNA-seq and microarray reveals gene expression signatures and pathway activation states. Proteomic profiling using mass spectrometry-based approaches quantifies protein abundance and post-translational modifications. Metabolomic analysis captures dynamic metabolic reprogramming in tumor cells and the tumor microenvironment. Multi-omics data integration, supported by bioinformatics and biostatistics expertise, enables network analysis and biomarker discovery with enhanced predictive power.
Non-invasive imaging technologies are essential for longitudinal monitoring of tumor progression, metastasis, and therapeutic response in living animals. Our small animal imaging platform includes bioluminescence imaging (BLI) for tracking luciferase-labeled tumor cells, fluorescence imaging (FLI) for visualizing targeted probes, micro-CT for anatomical and structural assessment, and magnetic resonance imaging (MRI) for soft tissue contrast. These modalities enable real-time quantification of tumor burden, evaluation of anti-metastatic efficacy, and assessment of drug biodistribution and tumor penetration. Imaging data are integrated with histopathological and molecular endpoints to provide a comprehensive preclinical efficacy package.
Combination regimens have become the standard of care in oncology, necessitating robust preclinical platforms to evaluate drug synergy, sequence dependency, and resistance mechanisms. Our combination therapy exploration platform supports rational design and systematic evaluation of multi-agent combinations, including chemotherapy + immunotherapy, targeted therapy + immune checkpoint inhibitors, and dual immune checkpoint blockade. We employ validated synergy models such as Bliss independence and Loewe additivity, combined with longitudinal biomarker monitoring to identify optimal dosing schedules and predictive response signatures. This platform accelerates the identification of clinically translatable combination strategies with enhanced therapeutic indices.
Why Choose Alfa Cytology?
Alfa Cytology stands at the intersection of scientific excellence and operational agility, offering a differentiated value proposition for preclinical oncology research. Our commitment to quality, innovation, and client partnership ensures that every study is executed with precision and purpose.
- Integrated platform spanning in vivo pharmacology, PK/PD, biomarker analysis, IHC/IF, flow cytometry, NGS, omics, and imaging under one roof.
- Extensive model portfolio with validated experience across 200+ preclinical oncology models including CDX, PDX, syngeneic, GEMM, and humanized systems.
- Regulatory-aligned study execution with GLP-capable facilities and quality management systems designed to support IND-enabling data packages.
- Multidisciplinary project teams comprising Ph.D.-level scientists, board-certified pathologists, veterinary surgeons, and biostatisticians for comprehensive study oversight.
- Flexible study designs accommodating diverse therapeutic modalities including small molecules, biologics, ADCs, cell therapies, and combination regimens.
- Advanced analytical capabilities featuring multiplex IHC, spectral flow cytometry, whole-genome/exome sequencing, and multi-omics integration with bioinformatics support.
- Real-time data transparency through secure client portals and structured milestone reporting for efficient project management and decision-making.
- Proven track record of accelerating oncology pipelines with robust, reproducible data that meets the stringent requirements of global regulatory agencies.
Contact Us
Ready to advance your oncology pipeline with confidence? Contact us today to discuss your preclinical study requirements and discover how Alfa Cytology's integrated platform can accelerate your path from discovery to clinic. Our scientific team is available to provide detailed project consultations, feasibility assessments, and customized proposals tailored to your therapeutic program. Reach out to us now and let us partner with you to transform promising science into transformative therapies.
Reference
- Wang, Yufei, et al. "Preclinical models for development of immune–oncology therapies." Immuno-oncology insights 3.8 (2022): 379.
For research use only. Not intended for any clinical use.
